Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center - Natrona Heights
mi
from
Natrona Heights, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center - Natrona Heights
mi
from
Natrona Heights, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Paoli Memorial Hospital
mi
from
Paoli, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Paoli Memorial Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC-Saint Clair Hospital Cancer Center
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC-Saint Clair Hospital Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC-Saint Margaret
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC-Saint Margaret
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Reading Hospital
mi
from
West Reading, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Reading Hospital
mi
from
West Reading, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Gibbs Cancer Center-Pelham
mi
from
Greer, SC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Gibbs Cancer Center-Pelham
mi
from
Greer, SC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA at South Austin Cancer Center
mi
from
Austin, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA at South Austin Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Grapevine
mi
from
Grapevine, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Grapevine
mi
from
Grapevine, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Longview Cancer Center
mi
from
Longview, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Longview Cancer Center
mi
from
Longview, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Round Rock Cancer Center
mi
from
Round Rock, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Round Rock Cancer Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Sandra L. Maxwell Cancer Center
mi
from
Cedar City, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Sandra L. Maxwell Cancer Center
mi
from
Cedar City, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Logan Regional Hospital
mi
from
Logan, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Logan Regional Hospital
mi
from
Logan, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Intermountain Medical Center
mi
from
Murray, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
McKay-Dee Hospital Center
mi
from
Ogden, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
McKay-Dee Hospital Center
mi
from
Ogden, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Utah Valley Regional Medical Center
mi
from
Provo, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Utah Valley Regional Medical Center
mi
from
Provo, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Dixie Medical Center Regional Cancer Center
mi
from
Saint George, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Dixie Medical Center Regional Cancer Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Utah Cancer Specialists-Salt Lake City
mi
from
Salt Lake City, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Utah Cancer Specialists-Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest-North Spokane
mi
from
Spokane, WA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest-North Spokane
mi
from
Spokane, WA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Compass Oncology Vancouver
mi
from
Vancouver, WA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Compass Oncology Vancouver
mi
from
Vancouver, WA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Langlade Hospital and Cancer Center
mi
from
Antigo, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Langlade Hospital and Cancer Center
mi
from
Antigo, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Bay Area Medical Center
mi
from
Marinette, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Community Memorial Hospital
mi
from
Menomonee Falls, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Community Memorial Hospital
mi
from
Menomonee Falls, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Solano Medical Center/Cancer Center
mi
from
Vallejo, CA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Solano Medical Center/Cancer Center
mi
from
Vallejo, CA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials